ChemoCentryx Stock Forecast, Price & News

ChemoCentryx (NASDAQ:CCXI) Frequently Asked Questions

Is ChemoCentryx a buy right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ChemoCentryx in the last twelve months. There are currently 1 hold rating, 6 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" ChemoCentryx stock.
View analyst ratings for ChemoCentryx or view top-rated stocks.

What stocks does MarketBeat like better than ChemoCentryx?

Wall Street analysts have given ChemoCentryx a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but ChemoCentryx wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting ChemoCentryx?

ChemoCentryx saw a drop in short interest in the month of September. As of September 15th, there was short interest totaling 3,730,000 shares, a drop of 16.6% from the August 31st total of 4,470,000 shares. Based on an average daily volume of 2,070,000 shares, the days-to-cover ratio is presently 1.8 days. Currently, 7.0% of the shares of the stock are sold short.
View ChemoCentryx's Short Interest.

When is ChemoCentryx's next earnings date?

ChemoCentryx is scheduled to release its next quarterly earnings announcement on Monday, November 8th 2021.
View our earnings forecast for ChemoCentryx.

How were ChemoCentryx's earnings last quarter?

ChemoCentryx, Inc. (NASDAQ:CCXI) issued its earnings results on Sunday, August, 8th. The biopharmaceutical company reported ($0.56) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.55) by $0.01. The biopharmaceutical company had revenue of $1.81 million for the quarter, compared to analyst estimates of $4.85 million. ChemoCentryx had a negative net margin of 568.54% and a negative trailing twelve-month return on equity of 33.17%. The company's quarterly revenue was down 96.3% compared to the same quarter last year. During the same quarter last year, the business earned $0.29 EPS.
View ChemoCentryx's earnings history.

How has ChemoCentryx's stock been impacted by COVID-19?

ChemoCentryx's stock was trading at $41.54 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, CCXI stock has decreased by 16.8% and is now trading at $34.57.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for CCXI?

8 analysts have issued twelve-month price objectives for ChemoCentryx's shares. Their forecasts range from $38.00 to $107.00. On average, they expect ChemoCentryx's stock price to reach $72.63 in the next year. This suggests a possible upside of 110.1% from the stock's current price.
View analysts' price targets for ChemoCentryx or view top-rated stocks among Wall Street analysts.

Who are ChemoCentryx's key executives?

ChemoCentryx's management team includes the following people:

• Thomas J. Schall, Chairman, President & Chief Executive Officer
• Tausif Butt, Chief Operating Officer & Executive Vice President (LinkedIn Profile)
• Susan M. Kanaya, Chief Financial Officer, Secretary & Director
• Sangita Ghosh, Senior Vice President-Technical Operations
• Markus J. Cappel, Treasurer & Chief Business Officer

What is Thomas J. Schall's approval rating as ChemoCentryx's CEO?

10 employees have rated ChemoCentryx CEO Thomas J. Schall on Glassdoor.com. Thomas J. Schall has an approval rating of 58% among ChemoCentryx's employees. This puts Thomas J. Schall in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of ChemoCentryx's key competitors?

Some companies that are related to ChemoCentryx include Amgen (AMGN), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Seagen (SGEN), Alnylam Pharmaceuticals (ALNY), Exact Sciences (EXAS), Repligen (RGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Novavax (NVAX), Neurocrine Biosciences (NBIX), United Therapeutics (UTHR) and Exelixis (EXEL).
View all of CCXI's competitors.

What other stocks do shareholders of ChemoCentryx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ChemoCentryx investors own include Exelixis (EXEL), Energy Transfer (ET), Dynavax Technologies (DVAX), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), Amicus Therapeutics (FOLD), Inovio Pharmaceuticals (INO), OPKO Health (OPK), Advanced Micro Devices (AMD) and Arrowhead Pharmaceuticals (ARWR).

What is ChemoCentryx's stock symbol?

ChemoCentryx trades on the NASDAQ under the ticker symbol "CCXI."

Who are ChemoCentryx's major shareholders?

ChemoCentryx's stock is owned by many different retail and institutional investors. Top institutional investors include Belvedere Trading LLC (0.06%) and Strs Ohio (0.02%). Company insiders that own ChemoCentryx stock include (International) Ltd Vifor, Geoffrey M Parker, James L Tyree, Markus J Cappel, Pui San Kwan, Susan M Kanaya, Tausif Butt, Thomas A Edwards and Thomas J Schall.
View institutional ownership trends for ChemoCentryx.

Which major investors are selling ChemoCentryx stock?

CCXI stock was sold by a variety of institutional investors in the last quarter, including Strs Ohio. Company insiders that have sold ChemoCentryx company stock in the last year include (International) Ltd Vifor, Geoffrey M Parker, James L Tyree, Markus J Cappel, Pui San Kwan, Thomas A Edwards, and Thomas J Schall.
View insider buying and selling activity for ChemoCentryx or view top insider-selling stocks.

Which major investors are buying ChemoCentryx stock?

CCXI stock was bought by a variety of institutional investors in the last quarter, including Belvedere Trading LLC.
View insider buying and selling activity for ChemoCentryx or or view top insider-buying stocks.

How do I buy shares of ChemoCentryx?

Shares of CCXI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ChemoCentryx's stock price today?

One share of CCXI stock can currently be purchased for approximately $34.57.

How much money does ChemoCentryx make?

ChemoCentryx has a market capitalization of $2.42 billion and generates $64.89 million in revenue each year. The biopharmaceutical company earns $-55.36 million in net income (profit) each year or ($0.84) on an earnings per share basis.

How many employees does ChemoCentryx have?

ChemoCentryx employs 133 workers across the globe.

What is ChemoCentryx's official website?

The official website for ChemoCentryx is www.chemocentryx.com.

Where are ChemoCentryx's headquarters?

ChemoCentryx is headquartered at 850 MAUDE AVENUE, MOUNTAIN VIEW CA, 94043.

How can I contact ChemoCentryx?

ChemoCentryx's mailing address is 850 MAUDE AVENUE, MOUNTAIN VIEW CA, 94043. The biopharmaceutical company can be reached via phone at (650) 210-2900 or via email at [email protected].